CR20220465A - Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos - Google Patents

Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos

Info

Publication number
CR20220465A
CR20220465A CR20220465A CR20220465A CR20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A CR 20220465 A CR20220465 A CR 20220465A
Authority
CR
Costa Rica
Prior art keywords
methods
formulations
same
human anti
tslp antibodies
Prior art date
Application number
CR20220465A
Other languages
English (en)
Inventor
Lauren Roschen
Jennifer Litowski
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20220465A publication Critical patent/CR20220465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente composiciones que comprenden más de aproximadamente 100 mg/mL de un anticuerpo anti-TSLP, un tensioactivo, prolina y un amortiguador que comprende más de aproximadamente 100 mg/mL de un anticuerpo anti-TSLP, un tensioactivo, prolina y un amortiguador. Además, se proporcionan métodos para tratar una enfermedad inflamatoria en un sujeto.
CR20220465A 2020-02-18 2021-02-18 Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos CR20220465A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062978201P 2020-02-18 2020-02-18
PCT/US2021/018561 WO2021168100A1 (en) 2020-02-18 2021-02-18 Formulations of human anti-tslp antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
CR20220465A true CR20220465A (es) 2023-03-30

Family

ID=74860588

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220465A CR20220465A (es) 2020-02-18 2021-02-18 Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos

Country Status (19)

Country Link
US (1) US20230081261A1 (es)
EP (1) EP4106811A1 (es)
JP (1) JP2023513833A (es)
KR (1) KR20220143699A (es)
CN (1) CN115151276A (es)
AR (1) AR121368A1 (es)
AU (1) AU2021221998A1 (es)
BR (1) BR112022016456A2 (es)
CA (1) CA3167975A1 (es)
CL (1) CL2022002251A1 (es)
CO (1) CO2022013251A2 (es)
CR (1) CR20220465A (es)
IL (1) IL295511A (es)
JO (1) JOP20220193A1 (es)
MX (1) MX2022010120A (es)
PE (1) PE20230115A1 (es)
TW (1) TW202144004A (es)
UY (1) UY39089A (es)
WO (1) WO2021168100A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4145105A1 (de) * 2021-09-06 2023-03-08 Anacyte Laboratories GmbH Lösung für die asservierung von zellen
CN118215681A (zh) * 2021-09-18 2024-06-18 江苏康宁杰瑞生物制药有限公司 包含pd-l1抗原结合片段的组合物及其用途
CN116251181B (zh) * 2021-12-02 2023-09-22 北京东方百泰生物科技股份有限公司 一种抗tslp单克隆抗体的注射制剂
WO2024092064A1 (en) * 2022-10-26 2024-05-02 Amgen Inc. Anti-tslp antibody compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2011056772A1 (en) 2009-11-04 2011-05-12 Schering Corporation Engineered anti-tslp antibody
TW201201840A (en) 2010-07-15 2012-01-16 Hoffmann La Roche Antibodies specifically binding to human TSLPR and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
EP3268032A1 (en) 2015-03-11 2018-01-17 GlaxoSmithKline Intellectual Property Development Limited Tslp binding proteins
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
EP3615065A1 (en) * 2017-04-28 2020-03-04 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
MX2019014615A (es) 2017-06-08 2020-02-07 Amgen Inc Dispositivo de administracion de farmacos accionado por par de torsion.
CN116832271A (zh) 2017-11-10 2023-10-03 安进公司 用于药物递送装置的柱塞
MA52013A (fr) 2018-03-13 2021-01-20 Amgen Inc Procédés de préparation de polypeptides résistant à la trypsine pour analyse par spectrométrie de masse
CN112789073B (zh) 2018-10-15 2023-09-15 安进公司 具有阻尼机构的药物递送装置
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament

Also Published As

Publication number Publication date
IL295511A (en) 2022-10-01
EP4106811A1 (en) 2022-12-28
WO2021168100A1 (en) 2021-08-26
BR112022016456A2 (pt) 2022-10-04
JOP20220193A1 (ar) 2023-01-30
UY39089A (es) 2021-08-31
US20230081261A1 (en) 2023-03-16
CN115151276A (zh) 2022-10-04
JP2023513833A (ja) 2023-04-03
CA3167975A1 (en) 2021-08-26
TW202144004A (zh) 2021-12-01
CL2022002251A1 (es) 2023-04-14
CO2022013251A2 (es) 2022-12-20
AU2021221998A1 (en) 2022-09-15
KR20220143699A (ko) 2022-10-25
PE20230115A1 (es) 2023-01-27
AR121368A1 (es) 2022-06-01
MX2022010120A (es) 2022-09-05

Similar Documents

Publication Publication Date Title
MX2022010120A (es) Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
JO3000B1 (ar) مركبات أجسام مضادة .
MX2019014023A (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
TW200602078A (en) Uses of anti-CTLA-4 antibodies
IN2012DN00313A (es)
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
TNSN08511A1 (en) Lyophilized formulations of anti-egfr antibodies
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
MY163480A (en) Sclerostin binding agents
SG163598A1 (en) Lawsonia vaccine and methods of use thereof
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
AR077611A1 (es) Metodo y conjunto de elementos ( kit) para tratar la adiccion a la nicotina. combinacion. uso.
Kim et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regulatory T cells
CR20220047A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
MX2022005249A (es) Anticuerpos anti-cd45 y conjugados de los mismos.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
MX2023000499A (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.
MX2021012782A (es) El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion.
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
WO2021257695A8 (en) Methods and compositions related to neutralizing antibodies against human coronavirus
EA200401523A1 (ru) Способы применения и композиции для диагностики и лечения инфекционного заболевания
MX2022014455A (es) Formulacion de anticuerpo anti-clever-1 estable.